A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy

Background: Chemotherapy is suggested to use in all stages of pancreatic cancer. Is it reasonable to recommend chemotherapy for all PDAC patients? It is necessary to distinguish low-risk PDAC patients underwent pancreatectomy, who may not lose survival time due to missed chemotherapy and not need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuqiang, Tian, Mengxiang, Zhou, Yuan, Tan, Fengbo, Liu, Wenxue, Zhao, Lilan, Perez, Daniel, Song, Xiangping, Wang, Dan, Nitschke, Christine, Pei, Qian, Güngör, Cenap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176415/
https://www.ncbi.nlm.nih.gov/pubmed/34093844
http://dx.doi.org/10.7150/jca.57768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176415/
https://www.ncbi.nlm.nih.gov/pubmed/34093844
http://dx.doi.org/10.7150/jca.57768

Ejemplares similares